ELISABETH HEATH, of Karmanos Cancer Institute, was presented with the Michigan Cancer Consortium’s inaugural Champion Award for 2016 for her efforts in curbing cancer. Heath has been with Karmanos Cancer Institute since 2003, appointed director of Prostate Cancer Research in 2010, and became a full professor at Wayne State University School of Medicine in 2013....
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
